Last reviewed · How we verify
CD1579 2.5%
At a glance
| Generic name | CD1579 2.5% |
|---|---|
| Also known as | Benzoyl Peroxide 2.5% |
| Sponsor | Galderma R&D |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients (PHASE1)
- Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris (PHASE3)
- Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris. (PHASE3)
- Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD1579 2.5% CI brief — competitive landscape report
- CD1579 2.5% updates RSS · CI watch RSS
- Galderma R&D portfolio CI